Acorai Health

Acorai Health develops a non-invasive cardiac and pulmonary pressure sensing platform that helps healthcare professionals identify hemodynamic congestion and personalize heart failure therapy without invasive procedures. The company's SAVE Sensor System is a first-of-its-kind multi-modal handheld platform built on Seismic, Acoustic, Visual, and Electric sensors, combined with machine learning to generate absolute intracardiac pressure insights including left-sided (PCWP) and right-sided (RAP) pressure measurements with hemodynamic congestion trends. The device has been clinically tested in over 2,000 patients across 20 hospitals in 6 countries, validated against Right Heart Catheterization as ground truth. The Acorai Heart Monitor is designed to be repeatable, easy to use, and portable for seamless clinical workflow integration, addressing critical healthcare challenges including reducing readmission rates and penalties, decreasing length of stay, and minimizing complications through continuous monitoring that improves medication decisions and patient stability. The platform has received FDA Breakthrough Device Designation and is undergoing ongoing clinical validation through the CAPTURE-HF study. Partners include Saint Luke's Health System, Bayer AG, Västra Götaland region, KHP Ventures, and EIT Health Gold Track program. Founded in 2019 and headquartered in Helsingborg, Sweden, Acorai has raised approximately $9 million at the Seed stage from investors including Solardis Health Ventures, CARMA FUND, Meridian Health Ventures, EIC Fund, and Loop Capital.